Short answer
Nuvalent, Inc. (NUVL) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026.
- Top risk flagged: FDA acceptance of NDA for zidesamtinib with PDUFA date September 18, 2026, critical regulatory milestone risk
FY2025 key financial metrics · XBRL
- Net income
- −$425M
- −63.1% YoY
- EPS (diluted)
- −$5.85
- −48.9% YoY
- ROE
- -34.1%
- −9.7 pp YoY
- Operating cash flow
- −$275M
- −48.7% YoY
Source: XBRL data from the Nuvalent, Inc. (NUVL) FY2025 10-K on SEC EDGAR. USD.
Nuvalent, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model focused on biopharmaceutical development and innovation
- No new products, services, or segments introduced or emphasized this year
- Maintained executive employment agreements with key leadership, including CEO James R. Porter and five other executives
- Proxy statement information (executive compensation, stock ownership, related transactions) incorporated by reference, not detailed herein
- Employment agreements amended in 2024 for James R. Porter and other executives, reflecting updated contractual arrangements
Management Discussion & Analysis
- Net loss $425.4M in 2025 vs $260.8M in 2024; operating cash outflow $275.2M vs $185.1M
- Operating cash flow decline due to higher clinical, manufacturing, personnel expenses; stock-based comp $86.5M vs $60.6M
- Cash, cash equivalents, and marketable securities $1.4B at 2025 year-end, expected to fund operations through 2029
- Investing cash outflow $124.1M in 2025, driven by $1.1B marketable securities purchases offset by $932.8M maturities
- Financing cash inflow $515.3M in 2025 from public offering ($472.5M net proceeds) and option exercises ($42M)
- Management highlights significant R&D and commercialization spending ahead, potential additional capital raises anticipated due to uncertain future funding needs
Risk Factors
- FDA acceptance of NDA for zidesamtinib with PDUFA date September 18, 2026, critical regulatory milestone risk
- Exposure to macroeconomic risks including inflation, interest rate fluctuations, and geopolitical tensions impacting funding access
- Dependence on contract manufacturing organizations (CMOs) for scale-up and commercial batch production of drug substances
- Market competition from ALECENSA (alectinib) in Phase 3 ALKAZAR trial for ALK-positive NSCLC targeting 450 patients
- Net losses expanding to $425.4 million in 2025 with $1.4 billion cash runway only through 2029, capital raise dependency risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.